A cure for early metastatic cancer and HIV that almost nobody knows about? Can it be true?
On November 19, 2008 something touched my life and changed it forever. I had just completed my second book, Outsmarting The Number One Killer (about how to prevent and reverse atherosclerotically-driven heart attacks and strokes) when I came across three seminal studies published earlier that year by internationally recognized research immunologist and molecular biologist, Nobuto Yamamoto, Ph.D. These pivotal papers—which I believe will change the course of medical history—blew me away: Yamamoto had apparently discovered a way to “outsmart” cancer, and was using the body’s own natural healing systems to do it.
“Holy cow!!!” I said to myself. “This guy has discovered a cure for early metastatic cancer. It appears to work 100% of the time!!! No one has ever done that before.” And this was no “black box” model or statistical study (you know, the kind that make observations but don’t address underlying causal mechanisms. Medicine A cures disease B, but nothing about how it actually works). All the basic science, all the necessary molecular biological information—an impressive display of published research studies from a quarter century of work—was right there for all to see. No smoke and mirrors. Anyone who has studied Dr. Yamamoto’s research papers would have to agree he published an impressively extensive series of serious science masterpieces.
As I learned more I became committed to bringing this powerful new set of ideas into public awareness. It became clear to me that we need to find a way to make GcMAF available to all cancer, HIV, and chronic virus patients, and we need to institute routine annual Nagalase testing to find cancers much earlier than imaging now allows.
If all new cancers were detected early by regular Nagalase testing, we could reverse them with GcMAF—long before X-rays could find them—and put cancer out of business once and for all. This may seem like a rash statement, but I believe it is supported by the facts.
Yamamoto’s three studies showed that incredibly small weekly doses (100 billionths of a gram—an amount that is invisible to the naked eye) of GcMAF had cured early metastatic breast, prostate, and colon cancers in 100% of (nonanemic) patients. In a fourth paper, he used the same treatment to cure 100% of nonanemic HIV-infected patients.
All of Yamamoto’s cancer patients had recently flunked the standard mainstream triad of surgery, chemo, and radiation. They had early metastatic disease, which means that despite the best efforts of conventional medicine, their cancers were out of control and still growing. Their prognoses were poor at best.
Curing metastatic cancer at all is rare. Until Professor Yamamoto discovered and administered GcMAF, no one had ever cured every single case. These are the patients oncologists give up on, the ones that get “palliative” care. Perhaps another round or two of chemo or radiation in the slim hopes of a long-term reversal or a little extra (probably not very high quality) time—but, with metastatic disease, there is no serious expectation of an actual cure. The numbers are profoundly dismal.
Granted, all of Yamamoto’s patients were in the earliest phase of metastatic disease and received GcMAF shortly after the Big Three had failed. For these patients (though a sprinkling might have been saved by additional radiation and/or chemo), the assumption is that their cancers would grow and eventually kill them. GcMAF, remarkably, saved every single one. This is an exceptional outcome and deserves greater scrutiny than it has received.
A fourth study, published in January of 2009, showed Yamamoto—using the same treatment protocol—had removed all signs of viral activity in 100% of HIV infected patients. All patients were free of HIV within 18 weeks. (One must wonder why the AIDS community hasn’t picked up the ball here and run with it?)
Remarkably, Yamamoto accomplished these cures relatively rapidly. The breast and prostate cancer patients were all cured in less than 6 months of weekly GcMAF injections. The colorectal cancer study took about a year to cure all subjects. Five to seven years of careful followup revealed no recurrences in any of the patients. Anyone who is familiar with cancer research would have to find this remarkable.
This was not a “one off,” a “lucky strike.” Yamamoto’s four papers were the culmination of decades of trailblazing research in which he had already proven—via basic science and animal studies—exactly how GcMAF and Nagalase work. The 2008 human trials were just the frosting on a phenomenal cake that took a quarter century to bake. The breadth and depth of the underlying research is important here because misinformed critics suggest that GcMAF is “unproved.” It seems doubtful these naysayers have read the dozens of Yamamoto papers published in peer-reviewed journals between 1979 and 2008 that lay down an unimpeachable foundation for his final proof.
My search for answers
When I first read Yamamoto’s studies, I couldn’t believe it either. A cure for early stage metastatic cancer that’s effective in every single case? Absurd. Published in peer-reviewed journals? No way. I figured there must be some hitch, a mistake, a logical error, a weak link, a fatal flaw—and I was determined to find it—but the deeper I delved, the more convinced I became that GcMAF was for real!
Then I started wondering why I seemed to be among the very few who “got it.”
At first, I spent a huge amount of time enhancing my understanding of the relevant molecular biology, genetics, and immunology. I learned a lot more than I anticipated about cancer, macrophages, oxidative bursts, adhesion molecules, antibodies, phagocytosis, protein chemistry, cytokines, messenger molecules, receptors, N-acetyl-galactosaminidase (Nagalase), and GcMAF. At times I felt as if I had stuffed so much new information into my head that it was going to explode. I needed to understand exactly how it all worked, how all the pieces fit together. I poured over research articles and molecular genetics texts until I felt I had a reasonable grasp of what Yamamoto was doing and saying. I developed the ability to visualize—in great detail—the workings of macrophages battling cancer cells and viruses in this brutal microscopic war.
The more I learned, the more it sunk in: using impeccable science, Yamamoto had found a powerful means of enhancing our bodies’ own anti-cancer, anti-viral weaponry! That’s what cured the cancers.
The more I learned the more I asked the question: why had the medical community—much less the average person—never heard of GcMAF? No article in the print media. No video, no book, no research articles other than Yamamoto’s. No serious scientific web discussions (which is truly extraordinary, because everything is on the internet). Nothing.
Next I turned to what I call “human browsers.” I called a bunch of my physician buddies and molecular biology colleagues—good scientists all—but there, too, I drew a blank every single time. Not a single one of them had ever heard of GcMAF.
Not easily dissuaded, I contacted several immunology researchers at major institutions, and again no one had heard of GcMAF. Maybe someone in the government or research establishments, the FDA (Food and Drug Administration), the NCI (National Cancer Institute), the NIH (National Institutes of Health), American Cancer Society (ACS) knew something? Nope. No one there had ever heard of it either. (Or if they had, they sure weren’t talking.)
In those early months, my level of frustration gradually escalated. Proof of a natural cure for advanced (metastatic) cancer (not to mention HIV and other chronic viral infections) and nobody seemed interested? I just couldn’t understand it.
Finally, a sense of surrealism set in. I had spent hundreds of hours on this, with literally nothing to show for it. Nobody knew anything. And when I tried to explain Yamamoto’s work to some of the people I called, I could hear their eyes were glazing over. I could hear them thinking, “C’mon now, doc. A cure for all cancers? Oh, sure. One that works 100% of the time? On metastatic cancer? Give me a break. It sounds like smoke and mirrors to me.” I started questioning my grasp on reality. No Oprah? No Larry King? No New York Times article? No article anywhere? No media coverage of any kind! No scientific recognition? What the heck is going on here?
Spreading the word about GcMAF
After writing an entire book on the subject, I can still honestly say I don’t know why the average person—not to mention the average physician or the average molecular biologist—has never heard of GcMAF. I hope that sharing this information will create the critical mass we need to overcome the obstacles. So: Hello out there! Here’s a cure for cancer and AIDS!!! It does have its limitations: the cancers must be early metastatiic—but that’s better than anything we have right now.
Even more significantly, here’s a way to rid the planet of the scourge of cancer. I am passing on what I have learned about it to enable you to chip in and work with me to transform GcMAF from a set of abstract concepts to a lifesaving reality. Millions upon millions of lives would be saved if we could make GcMAF—a harmless protein—available to the masses of cancer and HIV patients who desperately need it. And countless cancers would be prevented using Nagalase screening and GcMAF therapy on all adult human populations.
Please help! This is a two-way street. I’ve chosen a reader-editable format (actually, truth be known, my web genius friend and cyberguru, Peter Rowell created it specifically for this book) whereby anyone who is interested can contribute their ideas. The beauty of this approach is that it facilitates collective development of ideas by an organized community. Just scroll over the left vertical green bar, click to open a dialogue box, and share your ideas, edits, corrections, and questions. In doing so, you will have participated in a process that has the potential to help a lot of your fellow humans and to alleviate a huge amount of suffering.
And—as if that weren’t enough of a reward— you’ll also (if you so desire) be listed in the Acknowledgments.
Why GcMAF remains obscure
Here are a few key facts that provide a partial answer to the fascinating question: Why has GcMAF gone unnoticed?
A couple “brief asides” here, and then—in the next chapter—we’ll get into how GcMAF works.
Brief aside I:
Please don’t be intimidated by cell biology!
To the outsider, the world of molecular biology and biochemistry may seem bewildering and the language we use to describe cellular events often appears foreign and incomprehensible. Just because we use inscrutably complex words like group-specific component macrophage activating factor (GcMAF) or alpha-N-acetylgalactosaminidase (Nagalase) doesn’t mean the concepts are inaccessible. They aren’t. Please don’t be intimidated: this material is not as complicated as it might seem. My self-imposed job description has been to translate this arcane, esoteric, imposing, and highly technical science into concepts that are easily understood by the lay person—and, in the process, to bring it to life.
Brief aside II:
The war analogy: I use it because it works
For the same reason that language is the most popular and appropriate analogy for describing DNA and genetics, I have chosen the war analogy to depict the nano-scale drama that unfolds on the immunological battlefield: it works.
Please don’t think that this means I am pro-war. Quite the opposite. I think most wars are bad and stupid, and I detest them. We will have reached a high point in our evolution when we learn to put needless killing behind us once and for all.
Speaking as a humanoid member of a cell-based life form, however, it is crucial to acknowledge the necessity of this inner war against cancer and microbes, those evil forces that are out to destroy us. Pacifism won’t work here; we really have no choice but to fight back or die.